| Autor: |
Maia Oliveira, Iris Cristina, Vasconcelos Mallmann, Auriana Serra, Adelvane de Paula Rodrigues, Francisco, Teodorio Vidal, Laura Maria, Lopes Sales, Iardja Stéfane, Rodrigues, Gabriel Carvalho, Ferreira de Oliveira, Natalia, de Castro Chaves, Raquell, Cavalcanti Capibaribe, Victor Celso, Rodrigues de Carvalho, Alyne Mara, Maria de França Fonteles, Marta, Chavez Gutierrez, Stanley Juan, Barbosa-Filho, José Maria, Florenço de Sousa, Francisca Cléa |
| Předmět: |
|
| Zdroj: |
Neuropsychobiology; 2022, Vol. 81 Issue 1, p28-38, 11p |
| Abstrakt: |
Background: Depression is a common, chronic, and often recurrent serious mood disorder. Conventional antidepressants present limitations that stimulate the search for new drugs. Antioxidant and neuroprotective substances are potential antidepressant agents. In this context, riparin I (RIP I) has presented promising results, emerging as a potential source of a new therapeutic drug. In this study, the antidepressant effect of RIP I was evaluated in an animal model of depression induced by corticosterone (CORT). The involvement of neuroprotective and antioxidant mechanisms in the generation of this effect was also assessed. Methods: Female mice were submitted to CORT for 21 days and treated with RIP I in the last 7 days. Behavioral and neurochemical analyses were performed. Results: The administration of RIP I reversed the depressive and psychotic-like behavior, as well as the cognitive impairment caused by CORT, in addition to regulating oxidative stress parameters and BDNF levels in depression-related brain areas. Conclusion: These findings suggest that RIP I can be a strong candidate for drugs in the treatment of depression. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
